Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies

Citation
H. Celebi et al., Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies, BONE MAR TR, 26(2), 2000, pp. 211-214
Citations number
9
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Journal title
BONE MARROW TRANSPLANTATION
ISSN journal
02683369 → ACNP
Volume
26
Issue
2
Year of publication
2000
Pages
211 - 214
Database
ISI
SICI code
0268-3369(200007)26:2<211:FNIAAA>2.0.ZU;2-Y
Abstract
The risk and outcome of infection in febrile neutropenic patients is mainly determined by the duration of neutropenia, the underlying disease or the t reatment. This study was undertaken to compare infections and the outcome a fter conventional chemotherapy (CCT), allogeneic PBSC transplantation (allo PBSCT) or autologous PBSC transplantation (autoPBSCT), during the period of neutropenia, in a single center, A total of 145 patients (50 in CCT group, 50 in alloPBSCT and 45 in autoPBSCT) were evaluated, In the alloPBSCT grou p, 86% of the patients (43/50), in the autoPBSCT group 93% of the patients (42/45) and in the CCT group 92% (46/50) of the patients had at least one f ebrile episode during their neutropenic period (P > 0.05), Microbiologicall y and/or clinically documented infection rates were 50% (25/50), 42% (19/45 ) and 48% (24/50) respectively. Cram-positive pathogens, mostly coagulase-n egative staphylococci were the most frequent cause of bacteremias in all gr oups. The frequency of CNS infections was significantly higher in the alloP BSCT and autoPBSCT groups compared to the CCT group (P < 0.008 and P < 0.04 , respectively). Catheter infections were frequent ill the PBSCT groups and pulmonary infections were more frequent in the CCT group (P < 0.05), The C CT group needed longer antibiotic usage compared to the alloPBSCT group (P < 0.006), The duration of neutropenia and the type of treatment given, does not affect the rate of febrile episodes, but affects the type of infection s in febrile neutropenic patients.